1. Berger J, Gartner J. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 2006; 1763(12):1721-1732.

2. Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease
1. JAMA 2005; 294(24):3131-3134.

3. Hudspeth MP, Raymond GV. Immunopathogenesis of adrenoleukodystrophy: current understanding
1. J Neuroimmunol 2007; 182(1-2):5-12.

4. Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy
3. Brain 1997; 120 ( Pt 8):1485-1508.

5. Singh I, Moser AE, Moser HW, Kishimoto Y. Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res 1984; 18(3):286-290.

6. Singh I, Moser AE, Goldfischer S, Moser HW. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci U S A 1984; 81(13):4203-4207.

7. Mosser J, Douar AM, Sarde CO et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
5. Nature 1993; 361(6414):726-730.

8. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992; 8:67-113.

9. Cartier N, Lopez J, Moullier P et al. Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Proc Natl Acad Sci U S A 1995; 92(5):1674-1678.

10. Steinberg SJ, Kemp S, Braiterman LT, Watkins PA. Role of very-long-chain acyl-coenzyme A synthetase in X-linked adrenoleukodystrophy
1. Ann Neurol 1999; 46(3):409-412.

11. Moser HW, Moser AB, Smith KD et al. Adrenoleukodystrophy: phenotypic variability and implications for therapy
9. J Inherit Metab Dis 1992; 15(4):645-664.

12. Kemp S, Pujol A, Waterham HR et al. ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations
5. Hum Mutat 2001; 18(6):499-515.

13. Bezman L, Moser AB, Raymond GV et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001; 49(4):512-517.

14. Aubourg P, Blanche S, Jambaque I et al. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation
4. N Engl J Med 1990; 322(26):1860-1866.

15. van Geel BM, Assies J, Wanders RJ, Barth PG. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy
1. J Neurol Neurosurg Psychiatry 1997; 63(1):4-14.

16. Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications
1. J Neuropathol Exp Neurol 1992; 51(6):630-643.

17. Ito M, Blumberg BM, Mock DJ et al. Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation
1. J Neuropathol Exp Neurol 2001; 60(10):1004-1019.

18. Kumar AJ, Rosenbaum AE, Naidu S et al. Adrenoleukodystrophy: correlating MR imaging with CT
1. Radiology 1987; 165(2):497-504.

19. Kruse B, Barker PB, van Zijl PC, Duyn JH, Moonen CT, Moser HW. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy
1. Ann Neurol 1994; 36(4):595-608.

20. Pouwels PJ, Kruse B, Korenke GC, Mao X, Hanefeld FA, Frahm J. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy
1. Neuropediatrics 1998; 29(5):254-264.

21. Eichler FS, Barker PB, Cox C et al. Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy
3. Neurology 2002; 58(6):901-907.

22. Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy
1. J Neuropathol Exp Neurol 2000; 59(2):89-102.

23. Powers JM, DeCiero DP, Cox C et al. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria
1. J Neuropathol Exp Neurol 2001; 60(5):493-501.

24. van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 2001; 49(2):186-194.

25. Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW. Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening
12. J Pediatr 2005; 146(4):528-532.

26. Brennemann W, Kohler W, Zierz S, Klingmuller D. Occurrence of adrenocortical insufficiency in adrenomyeloneuropathy
5. Neurology 1996; 47(2):605.

27. Powers JM, Moser HW, Moser AB, Ma CK, Elias SB, Norum RA. Pathologic findings in adrenoleukodystrophy heterozygotes
2. Arch Pathol Lab Med 1987; 111(2):151-153.

28. el-Deiry SS, Naidu S, Blevins LS, Ladenson PW. Assessment of adrenal function in women heterozygous for adrenoleukodystrophy
3. J Clin Endocrinol Metab 1997; 82(3):856-860.

29. Laureti S, Casucci G, Santeusanio F, Angeletti G, Aubourg P, Brunetti P. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab 1996; 81(2):470-474.

30. Jorge P, Quelhas D, Oliveira P, Pinto R, Nogueira A. X-linked adrenoleukodystrophy in patients with idiopathic Addison disease
1. Eur J Pediatr 1994; 153(8):594-597.

31. Moser AB, Kreiter N, Bezman L et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls
1. Ann Neurol 1999; 45(1):100-110.

32. Moser AB, Moser HW. The prenatal diagnosis of X-linked adrenoleukodystrophy
4. Prenat Diagn 1999; 19(1):46-48.

33. Kelley RI, Datta NS, Dobyns WB et al. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes
3. Am J Med Genet 1986; 23(4):869-901.

34. Tullio-Pelet A, Salomon R, Hadj-Rabia S et al. Mutant WD-repeat protein in triple-A syndrome
1. Nat Genet 2000; 26(3):332-335.

35. Gazarian M, Cowell CT, Bonney M, Grigor WG. The "4A" syndrome: adrenocortical insufficiency associated with achalasia, alacrima, autonomic and other neurological abnormalities
3. Eur J Pediatr 1995; 154(1):18-23.

36. Boehm CD, Cutting GR, Lachtermacher MB, Moser HW, Chong SS. Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy
1. Mol Genet Metab 1999; 66(2):128-136.

37. Young RS, Ramer JC, Towfighi J, Weidner W, Lehman R, Moser HW. Adrenoleukodystrophy: unusual computed tomographic appearance
1. Arch Neurol 1982; 39(12):782-783.

38. Melhem ER, Loes DJ, Georgiades CS, Raymond GV, Moser HW. X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression
10. AJNR Am J Neuroradiol 2000; 21(5):839-844.

39. Eichler FS, Itoh R, Barker PB et al. Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: initial experience
1. Radiology 2002; 225(1):245-252.

40. Powers JM, Schaumburg HH. The adrenal cortex in adreno-leukodystrophy
1. Arch Pathol 1973; 96(5):305-310.

41. Powers JM, Schaumburg HH. Adreno-leukodystrophy (sex-linked Schilder's disease). A pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis
2. Am J Pathol 1974; 76(3):481-491.

42. Igarashi M, Schaumburg HH, Powers J, Kishmoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy
12. J Neurochem 1976; 26(4):851-860.

43. Powers JM, Moser HW, Moser AB, Schaumburg HH. Fetal adrenoleukodystrophy: the significance of pathologic lesions in adrenal gland and testis
2. Hum Pathol 1982; 13(11):1013-1019.

44. Peckham RS, Marshall MC, Jr., Rosman PM, Farag A, Kabadi U, Wallace EZ. A variant of adrenomyeloneuropathy with hypothalamic-pituitary dysfunction and neurologic remission after glucocorticoid replacement therapy
5. Am J Med 1982; 72(1):173-176.

45. Mahmood A, Dubey P, Moser HW, Moser A. X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes
4. Pediatr Transplant 2005; 9 Suppl 7:55-62.

46. Shapiro E, Krivit W, Lockman L et al. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy
1. Lancet 2000; 356(9231):713-718.

47. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo
5. Science 1988; 239(4837):290-292.

48. Moser HW, Loes DJ, Melhem ER et al. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients
1. Neuropediatrics 2000; 31(5):227-239.

49. Peters C, Charnas LR, Tan Y et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999
1. Blood 2004; 104(3):881-888.

50. Mahmood A, Raymond GV, Dubey P, Peters C, Moser HW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study
18. Lancet Neurol 2007; 6(8):687-692.

51. Rizzo WB, Leshner RT, Odone A et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy
1. Neurology 1989; 39(11):1415-1422.

52. van Geel BM, Assies J, Haverkort EB et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil"
1. J Neurol Neurosurg Psychiatry 1999; 67(3):290-299.

53. Kemp S, Wei HM, Lu JF et al. Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy
2. Nat Med 1998; 4(11):1261-1268.

54. Singh I, Khan M, Key L, Pai S. Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med 1998; 339(10):702-703.

55. Pai GS, Khan M, Barbosa E et al. Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients
5. Mol Genet Metab 2000; 69(4):312-322.

56. Doerflinger N, Miclea JM, Lopez J et al. Retroviral transfer and long-term expression of the adrenoleukodystrophy gene in human CD34+ cells
2. Hum Gene Ther 1998; 9(7):1025-1036.